Home Newsfeeds Quoin Pharmaceuticals Q4 EPS $(0.41) Beats $(0.62) Estimate

Quoin Pharmaceuticals Q4 EPS $(0.41) Beats $(0.62) Estimate

Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.62) by 33.87 percent.

byBenzinga Newsdesk

March 8, 2023

1 minute read

Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.62) by 33.87 percent.

Why Is Biogen Stock Trading Lower On Tuesday?

By Vandana Singh

February 13, 1:42 PM

Biogen's Q4 2023 performance, with $2.39 billion in sales, adjusted EPS of $2.95, and updates on key drugs.

BIIB

News

Porch Group Announces New Partnerships And Growth In Its Utilities Channel

By Benzinga Newsdesk

January 3, 5:07 PM

Porch Group, Inc. ("Porch", "Porch Group" or "the Company") (NASDAQ:PRCH), a leading vertical software company reinventing the home services and insurance industries, today announced growth in its utility concierge

EXC

Citigroup Maintains Buy on AutoZone, Raises Price Target to $2520

By Benzinga Newsdesk

September 20, 6:27 AM

Citigroup analyst Steven Zaccone maintains AutoZone (NYSE:AZO) with a Buy and raises the price target from $2250 to $2520.

AZO

Goldman Scrutinizes Hits, Misses, And Growth Trajectory Concerns For Eli Lilly And Its Its Obesity and Diabetes Drugs

By Vandana Singh

April 30, 3:11 PM

Eli Lilly boosts production for obesity and diabetes drugs, reports mixed Q1 results. Expectations for supply growth in 2024 outlined. Insights into payor access and reimbursement strategies discussed.

LLY

Quoin Pharmaceuticals Q4 EPS $(0.41) Beats $(0.62) Estimate

Related Posts

Why Is Biogen Stock Trading Lower On Tuesday?

Porch Group Announces New Partnerships And Growth In Its Utilities Channel

Citigroup Maintains Buy on AutoZone, Raises Price Target to $2520

Goldman Scrutinizes Hits, Misses, And Growth Trajectory Concerns For Eli Lilly And Its Its Obesity and Diabetes Drugs